Although pertussis remains a world-wide problem, whole-cell and acellular vaccines appear to induce short-lived immunity but do not prevent infection by the bacterium. The host with waning immunity may thereby serve as a reservoir for the infection of others. A novel bacterial virulence mechanism within the bvg locus of the B. pertussis genome, Brk, controls resistance to killing by the classical antibody-dependent pathway of complement. BrkA inhibits membrane attack complex formation at C5 by inhibiting C5 activation or deposition.
In Specific Aim 1, the size of the BrkA protein will be determined by N-terminal sequencing and its surface location will be defined by immunoelectron or immunofluorescent studies.
In Specific Aim 2, the region of BrkA responsible for serum resistance will be defined with the use of fusion proteins and truncation or deletion mutants. The BrkA resistance mechanism will be characterized by differentiating the effects of brkA on C5 activation or deposition and by identifying human proteins that interact with the BrkA fusion protein.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI038415-02
Application #
2633559
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Project Start
1997-01-01
Project End
2000-12-31
Budget Start
1998-01-01
Budget End
1998-12-31
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Cincinnati
Department
Genetics
Type
Schools of Medicine
DUNS #
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Millen, Scott H; Bernstein, David I; Connelly, Beverly et al. (2004) Antibody-mediated neutralization of pertussis toxin-induced mitogenicity of human peripheral blood mononuclear cells. Infect Immun 72:615-20
Mobberley-Schuman, Paula S; Connelly, Beverly; Weiss, Alison A (2003) Phagocytosis of Bordetella pertussis incubated with convalescent serum. J Infect Dis 187:1646-53
Barnes, M G; Weiss, A A (2001) BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition. Infect Immun 69:3067-72
Weingart, C L; Keitel, W A; Edwards, K M et al. (2000) Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults. Infect Immun 68:7175-9
Weingart, C L; Mobberley-Schuman, P S; Hewlett, E L et al. (2000) Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils. Infect Immun 68:7152-5
Lenz, D H; Weingart, C L; Weiss, A A (2000) Phagocytosed Bordetella pertussis fails to survive in human neutrophils. Infect Immun 68:956-9
Weingart, C L; Weiss, A A (2000) Bordetella pertussis virulence factors affect phagocytosis by human neutrophils. Infect Immun 68:1735-9
Weiss, A A; Mobberley, P S; Fernandez, R C et al. (1999) Characterization of human bactericidal antibodies to Bordetella pertussis. Infect Immun 67:1424-31
Weingart, C L; Broitman-Maduro, G; Dean, G et al. (1999) Fluorescent labels influence phagocytosis of Bordetella pertussis by human neutrophils. Infect Immun 67:4264-7
Fernandez, R C; Weiss, A A (1998) Serum resistance in bvg-regulated mutants of Bordetella pertussis. FEMS Microbiol Lett 163:57-63

Showing the most recent 10 out of 11 publications